Cryo Cell International (CCEL) Liabilities and Shareholders Equity (2010 - 2026)

Cryo Cell International (CCEL) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $60.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 5.79% year-over-year to $60.7 million; the TTM figure through May 2026 stood at $246.5 million (down 3.88% YoY), while the FY2025 annual figure was $61.7 million, down 4.56% from the prior year.
• Liabilities and Shareholders Equity held at $60.7 million in Q2 2026 per CCEL's latest filing, from $60.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $69.8 million in Q3 2023 and bottomed at $54.8 million in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $63.2 million across 5 years, with a median of $63.8 million in 2025.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity sank 47.93% — and 2023, when it rose 24.12%.
• Cryo Cell International's Liabilities and Shareholders Equity stood at $64.9 million in 2022, then retreated by 0.32% to $64.7 million in 2023, then changed by 0.0% to $64.7 million in 2024, then fell by 4.56% to $61.7 million in 2025, then decreased by 1.66% to $60.7 million in 2026.
• Business Quant data shows CCEL's Liabilities and Shareholders Equity at $60.7 million in Q2 2026, $60.9 million in Q1 2026, and $61.7 million in Q4 2025.